End Stage Renal Disease Market Size By Treatment (Transplant, Dialysis), By Diagnosis (Blood Test, Urine Test, Imaging Test), By End-use (Hospital and Clinics, Dialysis Centres), & Forecast, 2023 – 2032

End Stage Renal Disease Market Size By Treatment (Transplant, Dialysis), By Diagnosis (Blood Test, Urine Test, Imaging Test), By End-use (Hospital and Clinics, Dialysis Centres), & Forecast, 2023 – 2032

End Stage Renal Disease Market Size

End stage renal disease market was valued at around USD 114 billion in 2022 and is projected to reach over USD 183.9 billion by 2032. This incremental growth rate is owing to increasing prevalence of diabetes and hypertension coupled with rising number of patients suffering from end stage renal diseases (ESRD).
 

Aging population and growing demand for dialysis associated with technological advancement in diagnostic and treatment devices is anticipated to drive the market growth. Factors such as increasing prevalence of chronic kidney disease (CKD), rising awareness for early diagnosis of ESRD, and improving access to healthcare in developing regions is expected to further fuel the industry expansion.
 

Rising prevalence of diabetes, hypertension, obesity, and cardiovascular diseases contribute to increasing ESRD patient population. Technological advancements in diagnosis and treatment devices have led to improved treatment efficiency, patient comfort, and infection control measures. Emerging economies are witnessing growth due to increased awareness, improving healthcare infrastructure, and expanding reimbursement coverage. Major players in the market are emphasizing on research and development activities, strategic partnerships, and product innovation to maintain a competitive edge. Therefore, the end stage renal disease industry is witnessing substantial growth and innovation, driven by the demand for better diagnosis and treatment of chronic ailments and technological advancements in end stage renal disease treatment devices.
 

End-stage renal disease (ESRD) is a chronic diseases that indicates the final stage of chronic kidney disease (CKD) where the kidneys can no longer function adequately to sustain life. Patients suffering from ESRD require renal replacement therapy (RRT), that includes options such as kidney transplantation and dialysis treatments.

However, high cost associated with advance dialysis instruments can pose a significant challenge and impede the market growth in the coming years. Dialysis equipment, such as hemodialysis machines, peritoneal dialysis equipment, and related supplies, can be expensive to procure and maintain. For instance, the cost of hemodialysis machine can range between USD 10,000 to over USD 45,000 and can vary according to the advancements and technology installed. This high costs can place a significant financial burden on healthcare systems, especially in countries with limited healthcare budget. This financial strain can affect the availability and accessibility of dialysis treatments, thereby impacting the growth of the ESRD market.
 

The high capital investment required for equipment purchase, installation, maintenance, and regular upgrades can affect the financial viability of these providers. This financial burden limits the ability to expand their services, invest in new technologies, and offer competitive pricing. This, in turn, can impact the availability and quality of dialysis services in the market. Thus, the aforementioned factors are anticipated to impede the market progress.
 

COVID-19 Impact

The recent outbreak of COVID-19 had a marginal impact that influenced the end stage renal disease market revenue, specifically during the initial phase of 2020. The coronavirus outbreak proliferated the disease burden and hampered several global businesses including the healthcare sector, during the pandemic phase. These conditions impacted the market growth. Several hospitals and healthcare facilities globally experienced a significant decline in patient visits for diagnosis and treatment of end stage renal disease and dialysis procedures.
 

The COVID-19 pandemic reduced visits to healthcare facilities, causing medical services in several countries to be delayed, including kidney transplantation and dialysis procedures. The pandemic has disrupted global supply chains, causing delays in the production, delivery, and distribution of dialysis systems. During the pandemic, many healthcare systems faced significant strain due to the influx of COVID-19 patients. As a result, routine care and elective procedures, including regular dialysis treatments for ESRD patients, were disrupted or delayed in some areas.
 

 ESRD patients are considered immunocompromised and are at a higher risk of severe illness if they contract COVID-19. The fear of exposure to the virus and the need for stringent infection control measures resulted in reduced patient visits to healthcare facilities for dialysis treatments. However, some patients opted for home-based dialysis options to minimize their exposure to potential infections. This shift in treatment patterns have impacted the growth of in-center dialysis services. The global disruption of supply chains caused by the pandemic affected the availability and distribution of medical equipment, including dialysis machines, consumables, and pharmaceuticals. Manufacturing and shipping delays, increased demand, and restrictions on trade and transportation have led to shortages and increased prices of essential supplies for dialysis treatments.
 

End Stage Renal Disease Market Trends

Rising number of patients suffering from end stage renal diseases (ESRD) is anticipated to drive the market trends. Chronic kidney disease is one of the leading cause of end stage renal diseases that affects a significant number of people. For instance, according to the CDC data, in 2022, around 35.5 million people in the U.S. were suffering from chronic kidney disease and is expected to increase in the near future. As CKD progresses, a portion of these patients eventually develop ESRD, leading to an increased demand for end stage renal diseases treatments. The global ageing population, and older adults are more susceptible to developing CKD and ESRD. Age-related changes in kidney function, coupled with comorbidities, contribute to the higher prevalence of ESRD among older individuals. The growth of the aging population is expected to contribute to the increasing number of ESRD patients.
 

There has been a growing emphasis on early detection and diagnosis of CKD and ESRD. Increased awareness among healthcare professionals and the general population has led to improved screening and diagnostic practices, resulting in more accurate identification of individuals with CKD and early-stage ESRD. This improved diagnosis contributes to the growing number of patients in need of ESRD treatments. Improved availability of dialysis facilities, healthcare insurance coverage, and the establishment of dedicated ESRD centers in underserved areas ensure that more patients can receive timely and appropriate treatment, driving market progress. Technological advancements in dialysis equipment, pharmaceuticals, and surgical techniques for kidney transplantation have improved treatment outcomes and patient survival rates.
 

End Stage Renal Disease Market Analysis

Based on treatment, the end stage renal disease market is segmented as transplant and dialysis. The dialysis segment dominated the market accounting over 83% business share in 2022. The increasing demand for dialysis is owing to rising number of people suffering from end stage renal disease. Increasing prevalence of diabetes, hypertension, chronic kidney disease coupled with aging population is anticipated to drive the demand for dialysis across the globe. For instance, according to the International Diabetes Federation data, in 2022, around 783 million people globally were estimated to suffer from diabetes. This prevalent population necessitates the demand for dialysis as chronic kidney disease may lead to end stage renal disease.
 

Additionally, governments, healthcare organizations, and private providers have invested in expanding dialysis centers and improving infrastructure to ensure that more ESRD patients have access to dialysis treatments. This increased access has contributed to the growing demand for dialysis. Technological advancements in dialysis equipment and techniques have made dialysis treatments more effective, efficient, and convenient. Innovations such as high-flux membranes, improved dialysis machines, and home-based dialysis options have enhanced patient outcomes and comfort, making dialysis a more viable treatment option. These advancements have also contributed to increased demand for dialysis.
 

Based on diagnosis, the end stage renal disease market is segmented as blood test, urine test, imaging test and others. The blood test segment accounted for around USD 43.7 billion in 2022. Blood tests play a critical role in the diagnosis and monitoring of end stage renal disease. Screening blood tests, such as serum creatinine and estimated glomerular filtration rate (eGFR), help identify individuals with decreased kidney function. Increasing awareness regarding the importance of early detection, individuals are undergoing blood testing to assess their kidney health and identify any signs of kidney dysfunction or ESRD. Blood tests, including serum creatinine, blood urea nitrogen (BUN), and electrolyte panels, are routinely used to monitor kidney function in individuals with known kidney disease or ESRD. Such kidney function tests help assess the progression of kidney disease, monitor treatment effectiveness, and detect any complications that may arise.
 

Blood tests play a crucial role in the evaluation of potential kidney transplant recipients. These tests help assess the compatibility between the donor and recipient, detect potential infections or diseases that may impact the transplant outcome, and evaluate the overall health status of the recipient before transplantation. The development of more advanced and comprehensive blood tests, coupled with ongoing research and technological advancements, is estimated to play a significant role in improving the accuracy, efficiency, and accessibility of blood-based diagnostics for end stage renal disease.
 

Based on end-use, the end stage renal disease market is segmented as hospitals, dialysis centers and others. The hospitals segment held a dominant market share and accounted for around USD 55.4 billion in 2022. Hospitals provide a wide range of services including hemodialysis and peritoneal dialysis as well as perform kidney transplantation among patients suffering from end stage renal disease. Hospitals play a central role in diagnosing and managing ESRD patients, particularly in providing specialized care such as dialysis and kidney transplantation. Hospitals often have specialized departments, such as nephrology and urology, with expert healthcare professionals in managing end stage renal disease. These departments are equipped with the necessary infrastructure and technology to diagnose and treat ESRD effectively. Hospitals are incorporated with dialysis units within their premises, offering in-center hemodialysis or home-based dialysis options.
 

Additionally, hospitals also have dedicated transplant teams comprising surgeons, nephrologists, transplant coordinators, and other healthcare professionals with expertise in kidney transplantation. ESRD patients seek hospitals with established transplant programs to undergo evaluations, transplantation surgeries, and post-transplant care. ESRD often requires multidisciplinary comprehensive care involving various healthcare professionals to collaborate and manage the complexities associated with ESRD. The ability to provide integrated care within a hospital setting enhances patient outcomes and drives the demand for hospital-based end stage renal disease services. Hospitals offer advanced diagnostic facilities, including specialized laboratory testing, imaging techniques, and interventional procedures, to diagnose and manage ESRD.
 

North America region held a majority share in the end stage renal disease market and was valued at USD 51.1 billion in 2022. This high market share is ascribed to a variety of factors, including the presence of significant industry players, an increase in the number of patients suffering from end stage renal diseases, surging elderly population, among others. Hypertension is one of the major factor influencing the prevalence of end stage renal disease. For instance, according to the American Heart Association data, in 2022, over 122 million adults in America were suffering from hypertension. Additionally, around 15% adults suffering from hypertension were at the risk of kidney failure. This patient population increases the demand of dialysis and kidney transplantation for the diagnosis and treatment of end stage renal disease.
 

North America has well-developed healthcare systems that provide relatively widespread access to healthcare services. This includes access to specialist nephrology care, dialysis facilities, and kidney transplantation centers, enabling patients to seek timely diagnosis and treatment for ESRD. North America has a robust infrastructure for dialysis services, including in-center hemodialysis and home-based dialysis options such as peritoneal dialysis and home hemodialysis. The demand for dialysis services is increasing as more individuals require continuous renal replacement therapy.
 

End Stage Renal Disease Market Share

Some of the major players operating in the end stage renal disease market are

• AngioDynamics, Inc.
• Asahi Kasei Medical Co., Ltd.
• B. Braun Melsungen AG
• Baxter International, Inc.
• Becton Dickinson and Company
• Cantel Medical
• DaVita Inc.
• Fresenius Medical Care AG & Co. KGaA
• JMS Co. Ltd.
• Medtronic Plc
• Nikkiso Co., Ltd.
• Nipro Corporation
• Teleflex Incorporated
• Toray Industries Inc.
• U.S. Renal Care, Inc.

These leading market players are implementing advanced technologies to cater to the large unmet needs of the consumers.
 

End Stage Renal Disease Industry Leaders

• In May 2022, Medtronic plc and DaVita Inc. announced a strategic partnership to launch an independent medical device company that focuses on kidney and renal care. This company emphasizes on developing advance therapies for patients with kidney failure novel kidney care products and solutions, including future home-based products, to make different dialysis treatments more accessible to patients and improve overall outcomes. This strategic move helped the company to enhance their R&D capabilities and gain a competitive edge over its peers.
   
• In January 2019, Fresenius Medical Care announced the launch of 4008A dialysis machine in India to improve accessibility to life-sustaining dialysis treatment for patients who are living with from end-stage renal disease. This strategic launch helped the company to expand their geographic presence, thereby enhancing their customer base and generating business revenue.
   

End stage renal disease market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue (USD Million) from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Treatment, 2018 - 2032 (USD Million)

• Transplant
• Dialysis
  • Hemodialysis
  • Peritoneal Dialysis

By Diagnosis, 2018 - 2032 (USD Million)

• Blood Test
• Urine Test
• Imaging Test
• Others 

 By End-use, 2018 - 2032 (USD Million)

• Hospital and Clinics
• Dialysis Centres
• Others

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Sweden
  • The Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Thailand
  • Philippines
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Egypt
  • Turkey